IL5 (Reslizumab biosimilar) Antibody from ABBEXA LTD
Search, find, compare suppliers for anti-IL5 (Reslizumab biosimilar) antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | IL5 (Reslizumab biosimilar) |
| Clone | monoclonal |
| Host Species | Recombinant Human |
| Reactive Species | human |
| Isotype | IgG4-ND |
| Format | Protein A/G purified |
| Size | 100 µg, 1 mg, |
| Concentration | typically between 0.5-2.0 mg/ml. |
| Applications | ELISA, WB |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Reslizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IL5, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab inhibits IL-5-dependent cell proliferation, with an IC50 value of approximately 91. 1pM. Reslizumab has high binding affinity for human IL-5, with KD values of 109 pM and 4. 3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively. |
| Immunogen | n/a |
| Other Names | Reslizumab, IL5, 241473-69-8 |
| Gene, Accession # | CAS: 241473-69-8 |
| Catalog # | abx831156 |
| Price | please inquire |
| Order / More Info | IL5 (Reslizumab biosimilar) Antibody from ABBEXA LTD |
| Product Specific References | n/a |
ABBEXA LTD
ABBEXA LTD
181 Cambridge Science Park
Cambridge, CB4 0GJ UK
P: +44 (0) 1223 755950
Customer Service: info@abbexa.com
Technical Support: support@abbexa.com
Orders: orders@abbexa.com
https://www.abbexa.com
U.S. Office
118 Eldridge Rd, Suite C,
Sugar Land, TX 77478 USA
Telephone: +1 832 327 7413
Netherlands Office
Abbexa BV
Wattstraat 54 2723 RD,
Zoetermeer,Netherlands
Telephone: +44 (0) 1223 755950
Profile of ABBEXA LTD
Return to Antibodies